EUCTR2019-004952-13-BE进行中（未招募）1 期
Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART) - DART
niversity Hospital Ghent0 个研究点目标入组 140 人开始时间: 2020年8月14日最近更新:
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 140
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Male
入选标准
- •? Histologically proven initial diagnosis of adenocarcinoma of the prostate
- •? Biochemical relapse of PCa following radical local prostate treatment (radical prostatectomy (RP), primary radiotherapy or the combination of RP and prostate bed adjuvant/ salvage radiotherapy) according to the EAU guidelines 2018.
- •? Following RP, patients with a biochemical relapse are eligible in case a metastatic relapse is detected even in the absence of prior postoperative prostate bed radiotherapy (adjuvant or salvage). In the absence of prior prostate bed radiotherapy, prostate bed radiotherapy is mandatory for all pT3a or higher or patients with a positive margin at time of RP.
- •? For patients without prior RP that have a suspected local recurrence following primary radiotherapy, a biopsy should confirm local recurrence. Patients with a confirmed local recurrence and metastases are eligible in case they also undergo a local salvage therapy.
- •? Metastatic relapse on PSMA PET-CT with a maximum of 5 metastases (any M1a, M1b or M1c). Concomitant diagnosis of N1 disease is allowed as long as all lesions are treated with SBRT and the total number of lesions does not exceed 5. PSMA positive lesions will be scored using the MI-RADS scoring system with lesions scored 4 or 5 considered positive19.
- •? Asymptomatic for metastatic PCa
- •? Age ? Histologically proven initial diagnosis of adenocarcinoma of the prostate
- •? Biochemical relapse of PCa following radical local prostate treatment (radical prostatectomy (RP), primary radiotherapy or the combination of RP and prostate bed adjuvant/ salvage radiotherapy) according to the EAU guidelines 2018.
- •? Following RP, patients with a biochemical relapse are eligible in case a metastatic relapse is detected even in the absence of prior postoperative prostate bed radiotherapy (adjuvant or salvage). In the absence of prior prostate bed radiotherapy, prostate bed radiotherapy is mandatory for all pT3a or higher or patients with a positive margin at time of RP.
- •? For patients without prior RP that have a suspected local recurrence following primary radiotherapy, a biopsy should confirm local recurrence. Patients with a confirmed local recurrence and metastases are eligible in case they also undergo a local salvage therapy.
- •? Metastatic relapse on PSMA PET-CT with a maximum of 5 metastases (any M1a, M1b or M1c). Concomitant diagnosis of N1 disease is allowed as long as all lesions are treated with SBRT and the total number of lesions does not exceed 5. PSMA positive lesions will be scored using the MI-RADS scoring system with lesions scored 4 or 5 considered positive19.
- •? Asymptomatic for metastatic PCa
- •? Age >=18 years
- •? WHO class 0-1
- •? Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- •? Before patient registration/randomization, written informed consent must be given in accordance with to ICH/GCP, and national/local regulations.18 years
- •? WHO class 0-1
- •? Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- •? Before patient registration/randomization, written informed consent must be given in accordance with to ICH/GCP, and national/local regulat
排除标准
- •? Local relapse in the prostate gland or prostate bed not suitable for a local salvage treatment
- •? Small cell carcinoma of the prostate
- •? PSA doubling time >12 months
- •? Serum testosterone level <50ng/dl or 1.7 nmol/L at time of randomization
- •? Currently receiving ADT or PSA rise while on active treatment with ADT (LHRH-agonist, LHRH-antagonist, anti-androgen or estrogen) within the past 6 weeks
- •? Spinal cord compression or impending spinal cord compression
- •? Metastases in previously irradiated areas precluding safe delivery of SBRT
- •? Contraindications to darolutamide
- •? Previous treatment with cytotoxic agent for PCa
- •? Treatment during the past month with products known to influence PSA levels (e.g. fluconazole, finasteride, corticosteroids,…)
- •? Other active malignancy, except non-melanoma skin cancer or other malignancies with a documented disease-free survival for a minimum of 3 years.
研究者
相似试验
进行中（未招募）
1 期
Stereotactic body radiotherapy with or without Darolutamide for OligoRecurrent prostate cancer: a randomized phase II trial (DART)CTIS2024-511140-37-00niversitair Ziekenhuis Gent140
招募中
不适用
Potential abscopal effect of stereotactic body radiotherapy on the recurrence of hepatocellular carcinoma: An exploratory observation studyHepatocellular carcinomaJPRN-UMIN000038312ational Hospital Organization Nagasaki Medical Center280
已完成
2 期
Stereotactic body radiotherapy followed by surgical stabilization for patients with painful unstable spinal metastases: First-in-man study according to the IDEAL recommendationsmetastatic spine tumorspinal metastases100059591002747610005944NL-OMON42087niversitair Medisch Centrum Utrecht13
招募中
不适用
Stereotactic Body Radiotherapy for the Management of Prostate Cancer Local RecurrencesC61Malignant neoplasm of prostateDRKS00030837Europäisches Radiochirurgie Centrum München50
已完成
不适用
Efficacy of stereotactic body radiotherapy in primary renal cell carcinomaKCT0007835Asan Medical Center40